| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,397 | -828 |
| Gain on change in accounting estimates on contingent royalty liability | 1,933 | - |
| Change in fair value of financial instruments | -490 | 1,355 |
| Inventory write-down for excess & obsolescence | 178 | 178 |
| Loss on contingent liability | 25 | 25 |
| Loss on issuance of financial instruments | - | 0 |
| Stock-based compensation | 124 | 101 |
| Depreciation | 14 | 10 |
| Amortization of intangible asset | 410 | 330 |
| Noncash interest expense | 1,760 | 1,165 |
| Gain on debt extinguishment | - | 0 |
| Noncash right-of-use amortization | 95 | 61 |
| Net loss on disposal or impairment of property and equipment | -20 | -20 |
| Gain on accounts payable and accrued expenses settlements | 5,618 | 5,607 |
| Trade accounts receivable | -5,397 | -4,898 |
| Inventories | 285 | 507 |
| Prepaid and other assets | -500 | -77 |
| Accounts payable | -1,365 | -709 |
| Accrued expenses and other liabilities | 1,016 | 514 |
| Accrued compensation | 115 | -245 |
| Contingent liabilities | -475 | -425 |
| Operating lease liabilities | -94 | -62 |
| Net cash, cash equivalents and restricted cash used in operating activities | -2,023 | -2,359 |
| Payments related to asset acquisition | 57 | 57 |
| Purchases of property and equipment | 2 | 2 |
| Net cash, cash equivalents and restricted cash used in investing activities | -59 | -59 |
| Proceeds from issuance of aditxt notes related party | 2,425 | 2,425 |
| Borrowings under short-term debt and notes carried at fair value | 383 | 383 |
| Proceeds from reinstatement of merger agreement related party | - | 0 |
| Payments under short term debt and notes carried at fair value | 627 | 383 |
| Net cash, cash equivalents and restricted cash provided by financing activities | 2,181 | 2,425 |
| Net change in cash, cash equivalents and restricted cash | 99 | 7 |
| Cash and cash equivalents at beginning of period | 741 | - |
| Cash and cash equivalents at end of period | 840 | - |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)